Insider Buying: TELA Bio, Inc. (NASDAQ:TELA) CEO Purchases 88,888 Shares of Stock

TELA Bio, Inc. (NASDAQ:TELA) CEO Antony Koblish bought 88,888 shares of the business’s stock in a transaction dated Thursday, October 24th. The stock was acquired at an average cost of $2.25 per share, for a total transaction of $199,998.00. Following the purchase, the chief executive officer now owns 458,897 shares in the company, valued at approximately $1,032,518.25. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

TELA Bio Stock Down 2.6 %

Shares of NASDAQ:TELA traded down $0.07 during midday trading on Thursday, reaching $2.58. The company had a trading volume of 540,218 shares, compared to its average volume of 184,861. The stock has a market capitalization of $63.75 million, a P/E ratio of -1.50 and a beta of 0.99. The stock’s fifty day moving average price is $2.68 and its 200-day moving average price is $4.16. The company has a debt-to-equity ratio of 14.22, a current ratio of 3.41 and a quick ratio of 2.52. TELA Bio, Inc. has a one year low of $2.30 and a one year high of $7.84.

TELA Bio (NASDAQ:TELA) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.06). The company had revenue of $16.09 million for the quarter, compared to analyst estimates of $19.00 million. TELA Bio had a negative return on equity of 252.57% and a negative net margin of 65.04%. During the same period in the prior year, the business earned ($0.46) earnings per share. Equities research analysts expect that TELA Bio, Inc. will post -1.39 earnings per share for the current fiscal year.

Institutional Trading of TELA Bio

Several institutional investors and hedge funds have recently bought and sold shares of TELA. Russell Investments Group Ltd. grew its position in shares of TELA Bio by 107.6% in the 1st quarter. Russell Investments Group Ltd. now owns 94,940 shares of the company’s stock worth $538,000 after acquiring an additional 49,204 shares in the last quarter. Vanguard Group Inc. lifted its stake in TELA Bio by 0.7% during the first quarter. Vanguard Group Inc. now owns 1,006,052 shares of the company’s stock worth $5,704,000 after purchasing an additional 7,199 shares during the last quarter. First Light Asset Management LLC boosted its holdings in TELA Bio by 7.8% in the first quarter. First Light Asset Management LLC now owns 2,754,028 shares of the company’s stock worth $15,615,000 after purchasing an additional 199,387 shares during the period. Pentwater Capital Management LP raised its holdings in shares of TELA Bio by 29.6% during the second quarter. Pentwater Capital Management LP now owns 400,000 shares of the company’s stock worth $1,880,000 after purchasing an additional 91,358 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of TELA Bio during the second quarter worth $131,000. Institutional investors and hedge funds own 94.35% of the company’s stock.

Analysts Set New Price Targets

TELA has been the subject of several recent research reports. Piper Sandler lowered their price target on TELA Bio from $10.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. Canaccord Genuity Group reiterated a “buy” rating and set a $12.00 target price on shares of TELA Bio in a report on Friday, October 4th. Lake Street Capital decreased their price target on TELA Bio from $14.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, August 13th. Finally, JMP Securities dropped their price objective on shares of TELA Bio from $15.00 to $12.00 and set a “market outperform” rating on the stock in a research note on Tuesday, August 13th.

About TELA Bio

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.